Search
Monday, December 05, 2022

L.Hill, J&J Medical: “We’ll Help Health Without Surgery”

Lisa Ann Hill Was appointed general director of the division last January medical equipment spain of johnson and johnson, After 17 years at the company, Hill will be the first woman to hold the position at a pharmaceutical multinational.

This is the challenge for the new CEO “With determination and passion”, Achieving the goal: to develop in Spain.

“The industry is no longer as masculine as it used to be and more and more women are occupying important positions. But it is true that there is still work to be done to encourage young women to pursue careers in science.”Lisa Ann explains.

We talked to the new principal about this medical equipment spainChallenges that the company or vaccine will address jenson,

Present in more than 600 hospitals

– What is the status of the company and this division in our country?

,johnson and johnson is a leading healthcare company in the world, with over 134,000 employees and a presence of our products in over 175 countries.

The company has so far been divided into three lines of business: consumer products and self-care, pharmaceutical Janssen And we, medical devices, But from now on we’re gonna stay in two and focus on the medical part.

In medical devices, as the pioneer that we are in services, solutions and medical products; We drive smart, people-centric healthcare to help the patients we serve recover faster, live longer and live better.

Therefore, our division is essential to hospitals due to our expertise in developing products and services across the entire surgical environment.

Specifically, we are present in oncological and cardiovascular interventions; Also those associated with the surgical treatment of obesity, orthopedic, trauma and neurosurgery.

In Spain, we currently have about 550 employees and we are present in all public and private hospitals, over 600 in total.

We can proudly say that, we participate in almost 50% of surgical activity in this country, which helps more than two million patients in a year.

We are also a company of values, with a strong code of conduct based on the creed of the company that has guided us since 1943, with the kind of messages that we all have a role to play, regardless of our position in the organization. Without doing, and always focus on patients and professionals.

a cutting edge company

– What are the main challenges in this new phase? In which sectors and in which areas do you plan to invest?

-At this company we are very aware of our obligation to continue to grow year after year, in order to be able to contribute more and more to the health system and contribute to treating more patients and improving their quality of life.

We expect to once again increase the positive slope of our activity similar to the pre-pandemic years in which we grew double digits.

Perhaps because of the special situation we are experiencing at the moment, we should be a little more cautious, but we will always try to keep growing; If the pandemic gives us pause, normalizes surgical and medical activity at all levels.

It is our responsibility to be at the forefront of the market

With regard to investments, the company is always in constant growth to be able to offer quality services and solutions, as our responsibility is to be at the forefront of the market and anticipate the needs of patients and physicians.

For example, we have signed a strategic alliance with Microsoft Corporation for our digital surgery solution.

In fact medical devices We manufacture digital technologies ranging from robotic and surgical instruments to orthopedic instruments and interventional tools.

Therefore, the new platform will connect those devices with patient records and hospital information systems. BlueYou Microsoft Will help us develop a dashboard to monitor our digital surgery ecosystem.

We bought in February 2020 operation surgerya company of Google With which over the years we maintained a joint alliance to develop a new robotic surgery system.

in orthopedic surgery, just early last year, we got approval from FDA For VelisoThe Robotic Program for Orthopedic Surgery, to begin with, focuses on knee replacement.

Another company we acquired in 2017 was German Surgical Procedure Institute (SPI)A digital solution for standardization of surgical procedures to reduce variability and complications and which is giving us many breakthroughs and opportunities to collaborate with many hospitals.

– How do you plan to grow in Spain, organically or inorganically?

Our goal is to keep growing, providing added value to our physicians and patients.

In doing so, we understand that the way to achieve this is through a digital ecosystem in four areas that we face the challenge of continuing to consolidate and expand.

First, integrating care procedures before, during and after surgery. Second, digitizing and robotizing the operating room to standardize methods, reducing variability and making it less dependent on the individual capability of the surgical team. Third, logistics and administrative efficiency within the hospital. And, finally, the training of professionals.

cautiously optimistic

– Which prescription will be applicable for developing Johnson & Johnson Medical Devices in the Spanish market and in which areas of activity?

After the worst moments of the pandemic, we can say that we have managed to return to normal growth data as we were above 2019.

However, we still have to be vigilant, as the situation continues to produce a significant reduction in surgical activity and an apparent exhaustion of healthcare professionals, who have done a splendid job and for whom we will never be grateful enough.

According to some statistics, 5.3 million surgeries were performed in Spain in 2019. In 2020, due to the impact of the pandemic, there were 1.21 million surgeries, a decrease of 850,000 in public hospitals and 362,000 in private.

Of course, we’re going to work to help the health system not fix this activity and we’re going to be present in all the common areas in which we operate; Oncological procedures, particularly of the colon and lung, surgical treatment of obesity, with particular emphasis on the treatment of the ‘non-viral’ epidemic of the 21st century. With our contribution to the entire traumatology and orthopedics environment, with advances in knee and hip prostheses and sports medicine, maxillofacial and spinal surgery, without forgetting the treatment of arrhythmias and stroke; As well as the aesthetic and oncoplastic environment with our Breast Prosthesis Division.

We are living in the era of digitization and innovation. What can we expect from your company in these matters? Can big changes happen in the sector?

We have created a department dedicated specifically for this purpose, which has allowed us to activate collaborations with some 30 hospitals and we are currently in talks with some 40 more.

Medtech is a field that is constantly evolving. We are a company that is very aware of this development and we work towards the future.

For this reason, we have built our digital ecosystem as a foundation upon which we will continue to grow as a company.

Janssen Vaccine

The product that has garnered the most interest at Johnson & Johnson in recent times is the Janssen vaccine. Do you think you have lived up to the expectations?

We, as members of the great J&K family, are very proud of the great role of the vaccine developed by our Janssen colleagues.

The appearance of various vaccines has marked before and after

Without a doubt, the appearance of various vaccines has marked before and after the dire effects of the pandemic.

For more than a century, Johnson & Johnson has been active in fighting outbreaks ranging from Ebola to tuberculosis to HIV.

Our knowledge and experience, successes and failures, are contributing to everything we are currently doing to help eradicate COVID-19.

, Voices have been raised that the question is vacated on the grounds that they are influenced by the economic interests of pharmaceutical companies and doubt their real utility. What would you tell these people?

We have great respect for different opinions, but it is clear that there is a great medical-scientific consensus about the more than proven usefulness of vaccines.

Will vaccines eventually be the key to ending the COVID-19 pandemic?

We are absolutely convinced that it is the weapon to defeat the virus, as has been shown throughout history along with other diseases with which we live today.

Nation World News is the fastest emerging news website covering all the latest news, world’s top stories, science news entertainment sports cricket’s latest discoveries, new technology gadgets, politics news, and more.

Latest News

Related Stories